Ubs Group Ag Mirati Therapeutics, Inc. Put Options Transaction History

Ubs Group Ag

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 09, 2024	BUY	$41.99 - $62.38 $4,199 - $6,238	100 Added 0.08%	120,500 $7.08 Million
Q3 2023 Nov 09, 2023	BUY	$27.8 - $45.35 $2.7 Million - $4.41 Million	97,300 Added 421.21%	120,400 $5.24 Million
Q2 2023 Aug 11, 2023	SELL	$36.13 - $49.49 $90,325 - $123,725	-2,500 Reduced 9.77%	23,100 $834,000
Q1 2023 May 12, 2023	BUY	$36.54 - $54.26 $935,424 - $1.39 Million	25,600 New	25,600 $951,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.